Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

Alimentary Pharmacology and Therapeutics

Volumn 15, Issue 9, 2001, Pages 1479-1484

  Hokari, K ^a   Sugiyama, T ^a   Kato, M ^b   Saito, M ^a   Miyagishima, T ^a   Kudo, M ^a   Nishikawa, K ^a   Ishizuka, J ^a   Komatsu, Y ^a   Mizushima, T ^a   Kagaya, H ^a   Hige, S ^a   Takeda, H ^a   Asaka, M ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG METABOLISM; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; CLARITHROMYCIN; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROTON PUMPS; STOMACH ULCER;

EID: 0034851652     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2001.01063.x     Document Type: Article

References (31)

1. Chronic gastritis. A pathogenetic approach
2. Helicobacter pylori: Its epidemiology and its role in duodenal ulcer disease
3. An international association between Helicobacter pylori infection and gastric cancer
4. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori
5. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori
6. Short-term low-dose triple therapy for the eradication of Helicobacter pylori
7. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study
8. The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies
9. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole
10. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs
11. Review article: Cytochome P450 and the metabolism of proton pump inhibitors - Emphasis of rabeprazole
12. 13C-urea breath test in Japan
13. 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan
14. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans
15. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese
16. Biochemistry and molecular biology of the human CYP2C subfamily
17. What other regimens are under investigation to treat Helicobacter pylori infection
18. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intra-gastric acidity and plasma gastrin concentrations in young healthy male subjects
19. Efficacy of reduced dosage of rabeprazole in PPI/AC therapy for Helicobacter pylori infection
20. Helicobacter pylori-independent chronological change in gastric acid secretion in the Japanese
21. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects
22. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection
23. Geographic/interracial differences in polymorphic drug oxidation: Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19
24. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population
25. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer
26. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori
27. A multicenter, double-blind study on the triple therapy with lansoprazole/amoxicillin/clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients
28. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin and clarithromycin
29. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers
30. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori